Item 5.02 Departure of Directors or Certain Officers; Election of Directors;


           Appointment of Certain Officers; Compensatory Arrangements of Certain
           Officers.

(e) On January 14, 2021, Cyclacel Pharmaceuticals, Inc. (the "Company") agreed to extend the employment agreements (each, an "Employment Agreement," being extended by an "Extension Agreement") previously entered into with Spiro Rombotis, the President and Chief Executive Officer of the Company, and Paul McBarron, the Executive Vice President-Finance, Chief Financial Officer and Chief Operating Officer of the Company, such Extension Agreements to be effective as of January 1, 2021.

The terms of the Employment Agreements, which were previously disclosed under cover of Current Report on Form 8-K filed on January 7, 2019, remain unchanged, except that the term has been extended for another six months, through June 30, 2021.

Copies of the Extension Agreements are filed as Exhibits 10.1 and 10.2 hereto and are incorporated by reference.

Item 9.01 Financial Statements and Exhibits.






(d)    Exhibits.



Exhibit No. Description



  10.1        Employment Extension Agreement by and between Cyclacel
            Pharmaceuticals, Inc. and Spiro Rombotis, dated as of January 14,
            2021.
  10.2        Employment Extension Agreement by and between Cyclacel
            Pharmaceuticals, Inc. and Paul McBarron, dated as of January 14,
            2021.

© Edgar Online, source Glimpses